Which statement is true about NCCN guidelines for MRD in breast cancer?

Which statement is true about NCCN guidelines for MRD in breast cancer?

• A. There are no NCCN guidelines
• B. There are partial guidelines
• C. Guidelines exist only for metastatic disease
• D. There are comprehensive NCCN MRD guidelines

Answer: (A)

The statement tested here is about whether there are NCCN guidelines specifically for minimal residual disease in breast cancer. In practice, NCCN publishes comprehensive guidelines for breast cancer management that cover diagnosis, staging, systemic therapy, local therapy, and surveillance, but there is no separate, dedicated NCCN guideline set focused on minimal residual disease testing or management in breast cancer. MRD concepts, including ctDNA-based monitoring, are active areas of research and have not been codified into NCCN’s breast cancer guidelines. So the true point is that there are no MRD-specific NCCN guidelines for breast cancer.

The statement tested here is about whether there are NCCN guidelines specifically for minimal residual disease in breast cancer. In practice, NCCN publishes comprehensive guidelines for breast cancer management that cover diagnosis, staging, systemic therapy, local therapy, and surveillance, but there is no separate, dedicated NCCN guideline set focused on minimal residual disease testing or management in breast cancer. MRD concepts, including ctDNA-based monitoring, are active areas of research and have not been codified into NCCN’s breast cancer guidelines. So the true point is that there are no MRD-specific NCCN guidelines for breast cancer.